Övünç Suna ÖZTÜRK, Rıfat BOZKUŞ, Murat SUHER

Metabolik sendromu olan premenopozal ve postmenopozal kadınlarda serum androjen seviyeleri

Amaç: Premenopozal ve postmenopozal kadınlarda serum androjen seviyeleri ile metabolik sendrom komponentleri arasındaki ilişkinin araştırılmasıdır. Materyel ve Metot: Prospektif olarak yapılan çalışmaya 40 premenopozal, 50 postmenopozal toplam 90 metabolik sendromlu kadın dahil edildi. Metabolik sendrom tanısı Adult Treatment Panel (ATP) III kriterlerine göre belirlendi. Serum androjen seviyeleri, lipid parametreleri, açlık kan şekeri, insulin, insülin direnci, ürik asit seviyeleri çalışıldı. Tüm hastalarda antropometrik ölçümler ve kan basıncı ölçümü yapıldı. Hastalar sigara kullanımı, mensturasyon düzeni, menopoz yaşı ve hipertansiyon öyküsü açısından sorgulandı. Bulgular: Serbest testosteron bel çevresi, bel boy oranı, boyun çevresi, insülin ve HOMA indeksiyle pozitif olarak ilişkiliydi (p

Serum androgen levels in premenopausal and postmenopausal women with metabolic syndrome

Aim: To evaluate the relationship between androgen levels and metabolic syndrome components in premenopausal and postmenopausal women. Material and Methods: Ninety women (40 premenopausal and 50 postmenopausal) with metabolic syndrome were included in this prospective study. The metabolic syndrome diagnosis was defined according to the ATP III (Adult Treatment Panel III) criteria. Serum androgen levels, lipid parameters, fasting blood glucose, insulin, insulin resistance, uric acid levels were measured. Anthropometric measurements and blood pressure measurement were performed in all patients. Patients were asked about cigarette smoking, menstruation regularity, menopause age and hypertension history. Results: Free testosterone was positively associated with the waist circumference, weight to height ratio, neck circumference, insulin and HOMA index (p<0,05). After adjusting for factors that could affect free testosterone, free testosterone was most associated with the HOMA index. In the postmenopausal group free testosterone was higher than the premenopausal group but the difference was not statistically significant (p=0,090). Total testosterone levels were found similar in premenopausal and postmenopausal groups (p=0,865). Total testosterone was positively associated with body mass index, waist circumference and weigt to height ratio (p<0,05). After adjusting for factors that could affect total testosterone, total testosterone was most associated with weigth to height ratio. DHEAS was negatively associated with age and positively associated with neck circumference. While LDL, HDL and total cholesterol levels were higher in the postmenopausal group than the premenopausal group (p<0,05), triglyceride levels did not change significantly. Waist to hip ratio and body fat index was higher in postmenopausal group than the other group. Conclusion: In the pre and postmenopausal women with metabolic syndrome, total testosterone and free testosterone levels were not different, but if androgen levels were associated with the metabolic syndrome parameters separately, it would be significant.

PDF

___

1. Eckel RH. The metabolic syndrome. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al (eds). Harrison’s Principles of Internal Medicine. 17th ed. USA, Mc Graw Hill Medical 2008; 1509-14.
2. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004;89(6)2601-7.
3. Onat A, Sansoy V. Halkımızda koroner hastalığın baş suçlusu metabolik sendrom: sıklığı, unsurları, koroner risk ile ilişkisi ve yüksek risk kriterleri. Türk Kardiyol Dern Arş 2002;30:8-15.
4. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004;109:433-8.
5. Altuntaş Y. İnsülin direnci ve prediabet. Metabolik sendrom özel sayısı. Clinic Medicine 2008;4-13.
6. Metabolik Sendrom Kılavuzu. Türkiye Endokrinoloji ve Metabolizma Derneği 2009; 7-14.
7. Soliman NF, Wardle PG. The investigation and management of the hirsute woman. Rev In Gynaecologial Perinatal Practice 2006;23:1-8.
8. Burger HG. Androgen production in women. Fertil Steril 2002;77:3-5.
9. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. Arch Intern Med 2008;168(14): 1568-75.
10. Onat A, Uyarel H, Türkmen S, Hergenç G, Uzunlar B, Sarı İ, ve ark. Menopozal Türk kadınlarında serum testosteron düzeyleri ve koroner risk. Türk Kardiyol Dern Arş 2004;32:137-44.
11. Liu Y, Ding J, Bush TL, Longenecker JC, Nieto FJ, Golden SH, et al. Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation. Am J Epidemiol 2001;154(6):489-94.
12. Kalish GM, Barrett-Connor E, Laughlin GA, Gulanski BI. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial. J Clin Endocrinol Metab 2003;88(4):1646-52.
13. Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring) 2010;18(3): 604-10.
14. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88(6):2404-11.
15. Golden SH, Ding J, Szklo M, Schmidt MI, Duncan BB, Dobs A. Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: the atherosclerosis risk in communities study. Am J Epidemiol 2004;160:540-8.
16. Patel SM, Ratcliffe SJ, Reilly MP, Weinstein R, Bhasin S, Blackman MR, et al. Higher serum testosterone concentration in olderwomen is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2009;94(12):4776-84.
17. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone dehydroepiandrosterone sulphate and sex hormone binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85:2832–938.
18. Labrie F, Bélanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997;82:2396-402.
19. Tchernof A, Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol 2004; 151:1-14.
20. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990;12:321-331.
21. Peters HW, Westendorp IC, Hak AE, Grobbee DE, Stehouwer CD, Hofman A, et al. Menopausal status and risk factors for cardiovascular disease. J Intern Med 1999;246:521-8.
22. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 2000;24:226-31
23. Reckelhoff JF. Basic research into the mechanisms responsible for postmenopausal hypertension Int J Clin Pract Suppl 2004;139(58):13-9
24. Ünlühızarcı K, Keleştimur F. Hirsutizm. In: Erdoğan G. Endokrinoloji Temel ve Klinik, Ankara, MN Medikal Nobel Tıp Kitabevi 2005;654-59. Ö. S. Öztürk ve ark.